Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Partner Therapeutics, Inc.

https://www.partnertx.com

Latest From Partner Therapeutics, Inc.

Finance Watch: Notable Neuroscience VC Deals Include Nura Bio’s $73m Launch

Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.

Financing Neurology

Beyond COVID-19: Ousted BARDA Chief’s Whistleblower Complaint Suggests Widespread Politicization of HHS Funding Decisions

Ousted BARDA Director Rick Bright's whistleblower complaint cites a long-pattern of political interference in scientific decisions making and could lead to overhauls in how BARDA and other HHS contracts are awarded to the drug industry. It could also impact how Congress funds BARDA, following a recent move by lawmakers to give the division more direct control of its funding. 

Coronavirus COVID-19 Politics

Woodcock Said To Have Guided Hydroxychloroquine EUA In ‘Brokered Compromise’ To Limit Use

In whistleblower complaint, Rick Bright claims FDA Commissioner Hahn advocated for distributing hydroxychloroquine to pharmacies across the US, a departure from the approved emergency use authorization. Bright's complaint paints CDER Director Woodcock in a favorable light, saying she helped avoid an expanded access IND protocol for the potential coronavirus treatment.

Coronavirus COVID-19 Drug Review

Venture Funding Deals: Celularity Launches With $250m; Generation Bio Grabs $100m Series B

Celularity launched with $250m to develop cell therapies with technology licensed from Celgene and others, while mRNA specialist Moderna brought in another $500m mega round and Generation Bio closed a $100m Series B to fund ongoing gene therapy programs.

Financing StartUps and SMEs
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • PTx
UsernamePublicRestriction

Register